Comparative In vitro metabolism of purified mogrosides derived from monk fruit extracts

被引:10
作者
Bhusari, Sachin [1 ]
Rodriguez, Chester [1 ,5 ]
Tarka, Stanley M., Jr. [2 ]
Kwok, David [3 ]
Pugh, George [1 ]
Gujral, Jaspreet [4 ]
Tonucci, David [4 ]
机构
[1] Coca Cola Co, 1 Coca Cola Plaza NW, Atlanta, GA 30313 USA
[2] Tarka Grp Inc, 210 N Old Stonehouse Rd, Carlisle, PA 17015 USA
[3] BRI Biopharmaceut Res Inc, 101-8898 Heather St, Vancouver, BC V6P 3S8, Canada
[4] Tate & Lyle, 5450 Prairie Stone Pkwy, Hoffman Estates, IL 60192 USA
[5] Duke Univ, Dept Family Med & Community Hlth, Div Occupat & Environm Med, Toxicol Program, 2200 West Main St,Suite 400, Durham, NC 27705 USA
关键词
Mogrosides; In vitro metabolism; Anaerobic; Human safety; Monk fruit extracts; Mogrol;
D O I
10.1016/j.yrtph.2020.104856
中图分类号
DF [法律]; D9 [法律]; R [医药、卫生];
学科分类号
0301 ; 10 ;
摘要
Mogrosides are the primary components responsible for the sweet taste of Monk fruit which is derived from Siraitia grosvenorii (Swingle), a herbaceous plant native to southern China. Many mogrosides have been identified from Monk fruit extract, but the major sweetness component of Monk fruit by mass is mogroside V, comprising up to 0.5% of the dried fruit weight. Recent pharmacokinetic studies indicate that the parent mogrosides undergo minimal systemic absorption following ingestion and hydrolysis by digestive enzymes and/or intestinal flora and are excreted as mogrol (i.e., the aglycone) and its mono- and diglucosides. The objective of this study was to demonstrate whether individual mogrosides, are metabolized to a common and terminal deglycosylated metabolite, mogrol. An in vitro assay was conducted with pooled human male and female intestinal fecal homogenates (HFH) using mogrosides IIIe, mogroside V, siamenoside I, and isomogroside V at two concentrations over a 48 h period. The results show that various mogrosides that differ in the linkages and number of glucose units attached to a common cucurbitane backbone, share a common metabolic fate, and are metabolized within 24 h to mogrol. Aside from an apparent difference in the initial rate of deglycosylation between mogrosides at higher concentrations, no apparent difference in the rate of deglycosylation was observed between the male and female HFH. Given the similar structures of these mogrosides and a shared metabolic fate to mogrol, the study provides support for a reasonably conservative approach to assess safety based on bridging safety data from an individual mogroside (i.e., Mogroside V) to other mogrosides, and the establishment of a group Acceptable Daily Intake (ADI), rather than individual ADI' s for mogrosides.
引用
收藏
页数:11
相关论文
共 19 条
[1]  
Bechtel D., 2011, 359 GRN US FDA
[2]  
Cho S., 2015, 556 GRN US FDA
[3]  
Heimbach J., 2009, 301 GRN US FDA
[4]  
Heimbach J., 2016, 627 GRN US FDA
[5]   In vitro metabolism of the glycosidic sweeteners, stevia mixture and enzymatically modified stevia in human intestinal microflora [J].
Koyama, E ;
Kitazawa, K ;
Ohori, Y ;
Izawaa, O ;
Kakegawa, K ;
Fujino, A ;
Ui, M .
FOOD AND CHEMICAL TOXICOLOGY, 2003, 41 (03) :359-374
[6]   Liquid chromatography with tandem mass spectrometry method for the simultaneous determination of multiple sweet mogrosides in the fruits of Siraitia grosvenorii and its marketed sweeteners [J].
Luo, Zuliang ;
Shi, Hongwu ;
Zhang, Kailun ;
Qin, Xijun ;
Guo, Yuhua ;
Ma, Xiaojun .
JOURNAL OF SEPARATION SCIENCE, 2016, 39 (21) :4124-4135
[7]   In vitro AMPK activating effect and in vivo pharmacokinetics of mogroside V, a cucurbitane-type triterpenoid from Siraitia grosvenorii fruits [J].
Luo, Zuliang ;
Qiu, Feng ;
Zhang, Kailun ;
Qin, Xijun ;
Guo, Yuhua ;
Shi, Hongwu ;
Zhang, Lixia ;
Zhang, Zhonglian ;
Ma, Xiaojun .
RSC ADVANCES, 2016, 6 (09) :7034-7041
[8]   Twenty eight-day dietary toxicity study of Luo!Han fruit concentrate in Hsd:SD® rats [J].
Marone, P. A. ;
Borzelleca, J. F. ;
Merkel, D. ;
Heimbach, J. T. ;
Kennepohl, E. .
FOOD AND CHEMICAL TOXICOLOGY, 2008, 46 (03) :910-919
[9]  
MATSUMOTO K, 1990, CHEM PHARM BULL, V38, P2030, DOI 10.1248/cpb.38.2030
[10]  
McQuate R., 2014, 522 GRN US FDA